期刊
JOURNAL OF LOWER GENITAL TRACT DISEASE
卷 19, 期 2, 页码 91-96出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/LGT.0000000000000103
关键词
HPV; screening; cancer; pap; prevention; genotypes
资金
- Merck
- Hologic
- Roche
- Gen Probe
- GSK
- Bristol-Myers Squibb
- Photocure
- Cepheid
- PDS Biotechnologies
- Inovio
- Endocyte
- Fujiboro
- Eli Lilly
- Becton-Dickinson
In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology or cotesting (cytology in combination with high-risk HPV (hrHPV) testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective US-based registration study. Thirteen experts including representatives from the Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, American College of Obstetricians and Gynecologists, American Cancer Society, American Society of Cytopathology, College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the FDA for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for health care providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据